Baidu
map

PLOS ONE:科学家开发出新技术有效预测2型糖尿病风险!

2017-08-29 枫丹白露 来宝网

格拉斯哥大学的研究人员已经宣布了一种新的基于技术的方法,可以更准确地识别2型糖尿病高危人群。



新技术可预测2型糖尿病的风险】格拉斯哥大学的研究人员已经宣布了一种新的基于技术的方法,可以更准确地识别2型糖尿病高危人群。

希望在PLOS ONE上发表的调查结果可能有一天可以帮助解决全球2型糖尿病的增长,目前全球有4.15亿糖尿病患者,到2040年将达到6.42亿。

欧洲和美国的研究人员已经发现了潜在的新型预测因子或糖尿病的“生物标志物”,称为“微RNA”。经过进一步验证和跟进,研究人员认为这些可能成为糖尿病药物开发的新靶点。

2型糖尿病是以高血糖和严重的长期并发症为特征的常见疾病,包括眼睛,肾脏,神经和心脏病,降低预期寿命。目前,苏格兰有292,000名成年人(占人口的5.4%)患糖尿病。

研究主管,格拉斯哥大学心血管与医学科学研究所John Petrie教授说:“许多2型糖尿病可以通过早期和更强烈的干预来预防,以减少卡路里摄入量,增加体力活动并防止体重增加与现代生活方式。

“但是更准确的预测那些处于最大风险的手段是这项工作的重要组成部分,这个项目是大学和行业研究人员之间富有成效的合作的一个很好的例子,带来了尖端的技术,以应对重大的公共卫生问题,使用精心收集的来自良好表征的个体的样品。

在2型糖尿病患者发病前几年,分散在胰腺(β细胞)的细胞可以加班,产生额外的胰岛素,并保持血糖水平尽可能正常。

在糖尿病发展的时候,这些细胞已经变得“耗尽”了,不再能够制造足够的胰岛素来加工和储存食物。

研究人员研究了在发展为2型糖尿病前三年研究的血液样本中存在的蛋白质,并将其与同期保持正常血糖的年龄和体重相似的人群进行比较。

该项目测量了每个血液样品中的1,129个蛋白质以及已知调节基因表达的称为“微RNA”的754个分子。研究人员使用统计学模型来确定最适合预测糖尿病的方法。

值得注意的是,两种方法均标记了上皮 - 间质转化途径中的一系列分子。这是β细胞的一系列变化,可能反映出一种形式的“压力”,因为它们由于过度劳累而开始失去其胰岛素产生性质。

Petrie博士补充说:“我们今天与糖尿病研究界公开分享调查结果,希望我们的调查结果可以帮助全球努力应对目前2型糖尿病及其并发症的大流行。”

研究报告“开放获取期刊PLOS ONE”发表了“检测β细胞功能的新型生物标志物,并能早期发现2型糖尿病风险”。

原始出处:

Kirstine J. Belongie et al. Identification of novel biomarkers to monitor β-cell function and enable early detection of type 2 diabetes risk, PLOS ONE (2017). DOI: 10.1371/journal.pone.0182932.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1956290, encodeId=f7501956290fb, content=<a href='/topic/show?id=a74d1109c8' target=_blank style='color:#2F92EE;'>#2型糖尿病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1109, encryptionId=a74d1109c8, topicName=2型糖尿病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Fri Mar 16 10:13:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790031, encodeId=84361e9003108, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Nov 26 07:13:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903770, encodeId=c0321903e70cf, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Feb 23 18:13:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238615, encodeId=87d8238615ac, content=技术在发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62962078409, createdName=1531f1a381m, createdTime=Wed Aug 30 09:23:29 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238444, encodeId=fffa2384444b, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Tue Aug 29 22:21:40 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1956290, encodeId=f7501956290fb, content=<a href='/topic/show?id=a74d1109c8' target=_blank style='color:#2F92EE;'>#2型糖尿病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1109, encryptionId=a74d1109c8, topicName=2型糖尿病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Fri Mar 16 10:13:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790031, encodeId=84361e9003108, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Nov 26 07:13:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903770, encodeId=c0321903e70cf, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Feb 23 18:13:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238615, encodeId=87d8238615ac, content=技术在发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62962078409, createdName=1531f1a381m, createdTime=Wed Aug 30 09:23:29 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238444, encodeId=fffa2384444b, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Tue Aug 29 22:21:40 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1956290, encodeId=f7501956290fb, content=<a href='/topic/show?id=a74d1109c8' target=_blank style='color:#2F92EE;'>#2型糖尿病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1109, encryptionId=a74d1109c8, topicName=2型糖尿病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Fri Mar 16 10:13:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790031, encodeId=84361e9003108, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Nov 26 07:13:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903770, encodeId=c0321903e70cf, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Feb 23 18:13:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238615, encodeId=87d8238615ac, content=技术在发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62962078409, createdName=1531f1a381m, createdTime=Wed Aug 30 09:23:29 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238444, encodeId=fffa2384444b, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Tue Aug 29 22:21:40 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1956290, encodeId=f7501956290fb, content=<a href='/topic/show?id=a74d1109c8' target=_blank style='color:#2F92EE;'>#2型糖尿病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1109, encryptionId=a74d1109c8, topicName=2型糖尿病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Fri Mar 16 10:13:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790031, encodeId=84361e9003108, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Nov 26 07:13:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903770, encodeId=c0321903e70cf, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Feb 23 18:13:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238615, encodeId=87d8238615ac, content=技术在发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62962078409, createdName=1531f1a381m, createdTime=Wed Aug 30 09:23:29 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238444, encodeId=fffa2384444b, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Tue Aug 29 22:21:40 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-08-30 1531f1a381m

    技术在发展

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1956290, encodeId=f7501956290fb, content=<a href='/topic/show?id=a74d1109c8' target=_blank style='color:#2F92EE;'>#2型糖尿病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1109, encryptionId=a74d1109c8, topicName=2型糖尿病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Fri Mar 16 10:13:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790031, encodeId=84361e9003108, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Nov 26 07:13:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903770, encodeId=c0321903e70cf, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Feb 23 18:13:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238615, encodeId=87d8238615ac, content=技术在发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62962078409, createdName=1531f1a381m, createdTime=Wed Aug 30 09:23:29 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238444, encodeId=fffa2384444b, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Tue Aug 29 22:21:40 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-08-29 1771ae4158m

    学习一下很不错

    0

相关资讯

PLoS Comput Biol:研究揭示肺功能下降细节,或能“根除”慢性肺病!

克里斯托弗·马萨罗格斯大学的科学家们开发出了一种新的虚拟模型,可以详细对照不同因素导致的慢性肺部疾病炎症的改变。

JACC:糖尿病患者心血管疾病一级预防的目前进展

2017年8月,美国科学家发表在《J Am Coll Cardiol》的一篇文章介绍了糖尿病患者心血管疾病(CVD)一级预防的目前进展。

Exp Clin Endocr Diabe:警惕:前驱糖尿病人数已经超过糖尿病人数

近日,来自德国糖尿病研究中心发布了他们的研究数据,结果指出近四分之一的住院患者患有糖尿病,比例为22%,还有24%的住院患者有前驱糖尿病,进一步的研究结果证明,糖尿病患者住院时间更长,并发症的风险也更高。

J Am Coll Cardiol:T2DM老年患者:坎格列净能“保护”心血管

钠-葡萄糖协同转运蛋白2抑制剂或降低2型糖尿病(T2DM)患者心血管和心衰的风险。2017年8月,发表在《J Am Coll Cardiol》的一项研究调查了坎格列净对T2DM老年患者心血管生物标记物的影响。

Cell Rep:BMP4基因疗法:逆转2型糖尿病的新希望

在萨尔格学院的一项研究中,经过蛋白质BMP4基因治疗之后,即使摄入高能量饮食,体重没有增加,胰岛素敏感性也没有增加,完整的研究报告发表于《细胞》杂志中。

Circulation:2型糖尿病患者初始SGLT-2抑制剂治疗获益良多

2017年7月,发表在《Circulation》的由英国和瑞典科学家进行的CVD-REAL研究(钠-葡萄糖共转运载体-2抑制剂[SGLT-2i]新使用者的心血管结局的有效性比较),表明初始SGLT-2i治疗的患者比初始其他降糖药物治疗的患者的心衰和死亡风险低。

Baidu
map
Baidu
map
Baidu
map